356 related articles for article (PubMed ID: 23095864)
1. Teaching tolerance: New approaches to enzyme replacement therapy for Pompe disease.
Cousens LP; Mingozzi F; van der Marel S; Su Y; Garman R; Ferreira V; Martin W; Scott DW; De Groot AS
Hum Vaccin Immunother; 2012 Oct; 8(10):1459-64. PubMed ID: 23095864
[TBL] [Abstract][Full Text] [Related]
2. Immune Tolerance-Adjusted Personalized Immunogenicity Prediction for Pompe Disease.
De Groot AS; Desai AK; Lelias S; Miah SMS; Terry FE; Khan S; Li C; Yi JS; Ardito M; Martin WD; Kishnani PS
Front Immunol; 2021; 12():636731. PubMed ID: 34220802
[TBL] [Abstract][Full Text] [Related]
3. Optimizing treatment outcomes: immune tolerance induction in Pompe disease patients undergoing enzyme replacement therapy.
Chen HA; Hsu RH; Fang CY; Desai AK; Lee NC; Hwu WL; Tsai FJ; Kishnani PS; Chien YH
Front Immunol; 2024; 15():1336599. PubMed ID: 38715621
[TBL] [Abstract][Full Text] [Related]
4. A new assay for fast, reliable CRIM status determination in infantile-onset Pompe disease.
Wang Z; Okamoto P; Keutzer J
Mol Genet Metab; 2014 Feb; 111(2):92-100. PubMed ID: 24044919
[TBL] [Abstract][Full Text] [Related]
5. Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease.
Messinger YH; Mendelsohn NJ; Rhead W; Dimmock D; Hershkovitz E; Champion M; Jones SA; Olson R; White A; Wells C; Bali D; Case LE; Young SP; Rosenberg AS; Kishnani PS
Genet Med; 2012 Jan; 14(1):135-42. PubMed ID: 22237443
[TBL] [Abstract][Full Text] [Related]
6. HLA- and genotype-based risk assessment model to identify infantile onset pompe disease patients at high-risk of developing significant anti-drug antibodies (ADA).
De Groot AS; Kazi ZB; Martin RF; Terry FE; Desai AK; Martin WD; Kishnani PS
Clin Immunol; 2019 Mar; 200():66-70. PubMed ID: 30711607
[TBL] [Abstract][Full Text] [Related]
7. A Race Against Time-Changing the Natural History of CRIM Negative Infantile Pompe Disease.
Gupta P; Shayota BJ; Desai AK; Kiblawi F; Myridakis D; Messina J; Tah P; Tambini-King L; Kishnani PS
Front Immunol; 2020; 11():1929. PubMed ID: 33013846
[TBL] [Abstract][Full Text] [Related]
8. Antibody-mediated enzyme replacement therapy targeting both lysosomal and cytoplasmic glycogen in Pompe disease.
Yi H; Sun T; Armstrong D; Borneman S; Yang C; Austin S; Kishnani PS; Sun B
J Mol Med (Berl); 2017 May; 95(5):513-521. PubMed ID: 28154884
[TBL] [Abstract][Full Text] [Related]
9. Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance.
Sun B; Bird A; Young SP; Kishnani PS; Chen YT; Koeberl DD
Am J Hum Genet; 2007 Nov; 81(5):1042-9. PubMed ID: 17924344
[TBL] [Abstract][Full Text] [Related]
10. B-Cell depletion and immunomodulation before initiation of enzyme replacement therapy blocks the immune response to acid alpha-glucosidase in infantile-onset Pompe disease.
Elder ME; Nayak S; Collins SW; Lawson LA; Kelley JS; Herzog RW; Modica RF; Lew J; Lawrence RM; Byrne BJ
J Pediatr; 2013 Sep; 163(3):847-54.e1. PubMed ID: 23601496
[TBL] [Abstract][Full Text] [Related]
11. Benefits of Prophylactic Short-Course Immune Tolerance Induction in Patients With Infantile Pompe Disease: Demonstration of Long-Term Safety and Efficacy in an Expanded Cohort.
Desai AK; Baloh CH; Sleasman JW; Rosenberg AS; Kishnani PS
Front Immunol; 2020; 11():1727. PubMed ID: 32849613
[TBL] [Abstract][Full Text] [Related]
12. Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience.
Bali DS; Goldstein JL; Banugaria S; Dai J; Mackey J; Rehder C; Kishnani PS
Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):40-9. PubMed ID: 22252923
[TBL] [Abstract][Full Text] [Related]
13. Mapping the T helper cell response to acid α-glucosidase in Pompe mice.
Nayak S; Sivakumar R; Cao O; Daniell H; Byrne BJ; Herzog RW
Mol Genet Metab; 2012 Jun; 106(2):189-95. PubMed ID: 22494547
[TBL] [Abstract][Full Text] [Related]
14. CRIM-negative infantile Pompe disease: 42-month treatment outcome.
Rohrbach M; Klein A; Köhli-Wiesner A; Veraguth D; Scheer I; Balmer C; Lauener R; Baumgartner MR
J Inherit Metab Dis; 2010 Dec; 33(6):751-7. PubMed ID: 20882352
[TBL] [Abstract][Full Text] [Related]
15. Oral delivery of Acid Alpha Glucosidase epitopes expressed in plant chloroplasts suppresses antibody formation in treatment of Pompe mice.
Su J; Sherman A; Doerfler PA; Byrne BJ; Herzog RW; Daniell H
Plant Biotechnol J; 2015 Oct; 13(8):1023-32. PubMed ID: 26053072
[TBL] [Abstract][Full Text] [Related]
16. High dose IVIG successfully reduces high rhGAA IgG antibody titers in a CRIM-negative infantile Pompe disease patient.
Rairikar M; Kazi ZB; Desai A; Walters C; Rosenberg A; Kishnani PS
Mol Genet Metab; 2017 Sep; 122(1-2):76-79. PubMed ID: 28648664
[TBL] [Abstract][Full Text] [Related]
17. Characterization of immune response in Cross-Reactive Immunological Material (CRIM)-positive infantile Pompe disease patients treated with enzyme replacement therapy.
Desai AK; Kazi ZB; Bali DS; Kishnani PS
Mol Genet Metab Rep; 2019 Sep; 20():100475. PubMed ID: 31193175
[TBL] [Abstract][Full Text] [Related]
18. CRIM-negative infantile Pompe disease: characterization of immune responses in patients treated with ERT monotherapy.
Berrier KL; Kazi ZB; Prater SN; Bali DS; Goldstein J; Stefanescu MC; Rehder CW; Botha EG; Ellaway C; Bhattacharya K; Tylki-Szymanska A; Karabul N; Rosenberg AS; Kishnani PS
Genet Med; 2015 Nov; 17(11):912-8. PubMed ID: 25741864
[TBL] [Abstract][Full Text] [Related]
19. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants.
Kishnani PS; Goldenberg PC; DeArmey SL; Heller J; Benjamin D; Young S; Bali D; Smith SA; Li JS; Mandel H; Koeberl D; Rosenberg A; Chen YT
Mol Genet Metab; 2010 Jan; 99(1):26-33. PubMed ID: 19775921
[TBL] [Abstract][Full Text] [Related]
20. Immunodominant liver-specific expression suppresses transgene-directed immune responses in murine pompe disease.
Zhang P; Sun B; Osada T; Rodriguiz R; Yang XY; Luo X; Kemper AR; Clay TM; Koeberl DD
Hum Gene Ther; 2012 May; 23(5):460-72. PubMed ID: 22260439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
